复发风险及其对早期和局部高级NSCLC当前治疗策略的影响
Charlotte Tegenbosch1, Karolien Vekens2
1Respiratory Division, Department of Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium Charlotte.tegenbosch@vitaz.be.
Anticancer research
|December 3, 2024
概括
在非小细胞肺癌 (NSCLC) 中,疾病复发很常见. STK11突变,而不仅仅是TNM阶段,影响生存,表明需要个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 医学遗传学 医学遗传学
背景情况:
- 早期和局部晚期非小细胞肺癌 (NSCLC) 的复发率仍然很高,尽管有治愈治疗.
- 免疫检查点抑制剂 (ICI) 在II-III期NSCLC的 (新) 辅助剂环境中显示出生存益处.
- 确定预测复发的因素对于优化多模式治疗至关重要.
研究的目的:
- 确定非小细胞肺癌 (NSCLC) 患者疾病复发的诱导因素.
- 评估目前欧洲免疫检查点抑制剂 (ICI) 补偿标准的有效性.
- 探索STK11突变在预测结果中的作用.
主要方法:
- 对167名患有I-IIIA期NSCLC的患者进行了回顾性观察研究.
- 从2017-2021年间的胸部多学科瘤委员会讨论中收集的数据.
- 基于治疗方式,TNM阶段和遗传突变的复发率,复发时间和生存率的分析.
主要成果:
- 34%的患者出现了复发,中位时间为9.1个月.
- 在IIIA期NSCLC中,复发率最高 (56.5%).
- STK11突变与整体存活率较差显著相关;TNM阶段和治疗方式影响了复发和无进展存活率.
结论:
- 单独的TNM阶段不足以预测NSCLC的结果.
- 在手术治疗的NSCLC患者中,STK11突变状态是显著的预后因素.
- 将循环瘤DNA分析整合到外科手术期间的策略中,可能会改善治疗选择,减少过度和不足治疗.
关键词:
ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI IC1 ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI IC1 IC1 IC1 IC1 IC1 IC2 IC2 IC2 IC2 IC2 IC1 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which非小细胞肺癌是非小细胞肺癌.免疫检查点抑制剂免疫检查点抑制剂复发风险因素 复发风险因素追溯数据是追溯的数据.治疗策略 治疗策略更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
217
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Cancer Stem Cells and Tumor Maintenance
4.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
